UK Markets closed

Onxeo SA (0NWK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.3720+0.3720 (+75.09%)
At close: 06:23PM BST
Full screen
Previous close0.7305
Open0.3720
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.3720 - 0.3720
52-week range0.3720 - 0.3720
Volume1,500
Avg. volumeN/A
Market cap21.02M
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
EPS (TTM)-0.1230
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux

    PARIS, July 04, 2022--Regulatory News: Under the liquidity contract entered into between ONXEO (Paris:ALONX) (NASDAQ OMX:ONXEO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:

  • Business Wire

    Onxeo: Initial IND Application for AsiDNA Granted "Study May Proceed" by the U.S. FDA

    PARIS, June 30, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced that the U.S. Food and Drug Administration (FDA) has cleared the initial IND for its first-in-class drug candidate AsiDNA. This is the first US IND Onxeo filed since the US team came on board in

  • Business Wire

    Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022

    PARIS, June 16, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), ("Onxeo" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, announces that the Combined General Meeting held today adopted all resolutions presented, in accordance with the Board of Directors’ recommendations.